Payment overview · 2025
General Payments
$423.97
21 reported records · 7 companies
Healthcare provider profile · identity verified
Diego De La Mora, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · EL PASO, TX · NPI 1124349667
Verified facts
What the public records show
CMS Open Payments records show Diego De La Mora, M.D. received $423.97 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $169.99 | 40.1% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $66.63 | 15.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $58.34 | 13.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.98 | 12.7% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.64 | 8.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.84 | 5.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.55 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $423.97 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $154.76 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $73.66 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $39.09 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.31 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.64 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.54 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 86 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 42 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 96 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 108 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 103 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
96 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
86 | 86 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
100 | 77 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
103 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
59 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
42 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 487 | 173 |
| Metformin Hcl | Metformin Hcl | 361 | 132 |
| Lisinopril | Lisinopril | 354 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 292 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 272 | 85 |
| Losartan Potassium | Losartan Potassium | 244 | 90 |
| Omeprazole | Omeprazole | 169 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 154 | 62 |
| Gabapentin | Gabapentin | 152 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 57 |
| Furosemide | Furosemide | 125 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 48 |
| Jardiance | Empagliflozin | 108 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 54 |
| Mounjaro | Tirzepatide | 103 | 29 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 100 | 77 |
| Sertraline Hcl | Sertraline Hcl | 99 | 37 |
| Farxiga | Dapagliflozin Propanediol | 96 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 31 |
| Simvastatin | Simvastatin | 91 | 35 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 86 | 86 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 35 |
| Alendronate Sodium | Alendronate Sodium | 82 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 82 | 34 |
| Prednisone | Prednisone | 74 | 46 |
| Carvedilol | Carvedilol | 73 | 29 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 67 | 32 |
| Ozempic | Semaglutide | 65 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 27 |
| Trulicity | Dulaglutide | 59 | 18 |
| Glipizide | Glipizide | 57 | 21 |
| Montelukast Sodium | Montelukast Sodium | 55 | 18 |
| Mirtazapine | Mirtazapine | 54 | 21 |
| Finasteride | Finasteride | 51 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 47 |
| Januvia | Sitagliptin Phosphate | 49 | 16 |
| Trazodone Hcl | Trazodone Hcl | 49 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 30 |
| Famotidine | Famotidine | 47 | 16 |
| Ibuprofen | Ibuprofen | 47 | 33 |
| Meloxicam | Meloxicam | 46 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 22 |
| Glipizide Er | Glipizide | 45 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 18 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 44 | 18 |
| Eliquis | Apixaban | 42 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 16 |
| Sucralfate | Sucralfate | 42 | 17 |
| Incruse Ellipta | Umeclidinium Bromide | 40 | 13 |
| Allopurinol | Allopurinol | 39 | 15 |
| Tramadol Hcl | Tramadol Hcl | 39 | 14 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 38 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 15 |
| Rybelsus | Semaglutide | 36 | 13 |
| Ondansetron Odt | Ondansetron | 32 | 18 |
| Spironolactone | Spironolactone | 32 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | 12 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 19 |
| Memantine Hcl | Memantine Hcl | 29 | 14 |
| Ezetimibe | Ezetimibe | 28 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 24 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | 11 |
| Clotrimazole | Clotrimazole | 25 | 11 |
| Torsemide | Torsemide | 25 | 11 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | 12 |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | 12 |
| Metformin Hcl Er | Metformin Hcl | 22 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 16 |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Creon | Lipase/Protease/Amylase | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Lactulose | Lactulose | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 15 | 15 |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Jublia | Efinaconazole | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $423.97 · 21 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, JARDIANCE, MOUNJARO, NURTEC ODT, PREVNAR 20, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, XIFAXAN | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error